Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 424

1.

Combined inhibition of tumour necrosis factor-alpha and interleukin-12/23 for long-standing, refractory psoriatic disease: a differential role for cytokine pathways?

De Marco G, McGonagle D, Mathieson HR, Merashli M, Magee C, FitzGerald O, Goodfield M, Marzo-Ortega H.

Rheumatology (Oxford). 2018 Jul 4. doi: 10.1093/rheumatology/key199. [Epub ahead of print] No abstract available.

PMID:
29982709
2.

Advanced musculoskeletal physiotherapy practice in Ireland: A National Survey.

Fennelly O, Blake C, FitzGerald O, Breen R, O'Sullivan C, O'Mir M, Desmeules F, Cunningham C.

Musculoskeletal Care. 2018 Jun 21. doi: 10.1002/msc.1351. [Epub ahead of print]

PMID:
29927063
3.

Advanced practice physiotherapy-led triage in Irish orthopaedic and rheumatology services: national data audit.

Fennelly O, Blake C, FitzGerald O, Breen R, Ashton J, Brennan A, Caffrey A, Desmeules F, Cunningham C.

BMC Musculoskelet Disord. 2018 Jun 1;19(1):181. doi: 10.1186/s12891-018-2106-7.

4.

Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting.

Jadon DR, Chandran V, Stober C, Ogdie A, Armstrong AW, Callis Duffin K, Gladman DD, Helliwell PS, O'Sullivan D, de Wit M, FitzGerald O, Ritchlin CT.

J Rheumatol Suppl. 2018 Jun;94:54-61. doi: 10.3899/jrheum.180141.

PMID:
29858357
5.

GRAPPA 2017 Project Report.

Callis Duffin K, FitzGerald O, Kavanaugh A, Mease PJ, Merola JF, Ogdie A, O'Sullivan D, Reddy SM, Ritchlin CT, Coates LC.

J Rheumatol Suppl. 2018 Jun;94:48-51. doi: 10.3899/jrheum.180139.

PMID:
29858355
6.

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

Holland R, Tillett W, Ogdie A, Leung YY, Gladman DD, Callis Duffin K, Coates LC, Mease PJ, Eder L, Strand V, Elmamoun M, Højgaard P, Chau J, de Wit M, Goel N, Lindsay CA, FitzGerald O, Shea B, Beaton D, Orbai AM.

J Rheumatol Suppl. 2018 Jun;94:17-25. doi: 10.3899/jrheum.180142.

PMID:
29858348
7.

Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelines.

Murray KE, Moore L, O'Brien C, Clohessy A, Brophy C, Minnock P, FitzGerald O, Molloy ES, Mongey AB, Higgins S, Higgins MF, Mc Auliffe FM, Veale DJ.

Ir J Med Sci. 2018 May 10. doi: 10.1007/s11845-018-1829-7. [Epub ahead of print]

PMID:
29748892
8.
9.

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.

van der Heijde D, Deodhar A, FitzGerald O, Fleischmann R, Gladman D, Gottlieb AB, Hoepken B, Bauer L, Irvin-Sellers O, Khraishi M, Peterson L, Turkiewicz A, Wollenhaupt J, Mease PJ.

RMD Open. 2018 Mar 14;4(1):e000582. doi: 10.1136/rmdopen-2017-000582. eCollection 2018. Erratum in: RMD Open. 2018 Mar 26;4(1):.

10.

Work Outcomes in Patients Who Stay at Work Despite Musculoskeletal Pain.

Cochrane A, Higgins NM, Rothwell C, Ashton J, Breen R, Corcoran O, FitzGerald O, Gallagher P, Desmond D.

J Occup Rehabil. 2017 Dec 13. doi: 10.1007/s10926-017-9748-4. [Epub ahead of print]

PMID:
29236203
11.

Higher Coronary Plaque Burden in Psoriatic Arthritis Is Independent of Metabolic Syndrome and Associated With Underlying Disease Severity.

Szentpetery A, Healy GM, Brady D, Haroon M, Gallagher P, Redmond CE, Fleming H, Duignan J, Dodd JD, FitzGerald O.

Arthritis Rheumatol. 2018 Mar;70(3):396-407. doi: 10.1002/art.40389. Epub 2018 Feb 6.

PMID:
29193860
12.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS.

Arthritis Rheumatol. 2018 Mar;70(3):345-355. doi: 10.1002/art.40391. Epub 2018 Feb 6.

PMID:
29193765
13.

Remission in psoriatic arthritis-where are we now?

Coates LC, Conaghan PG, D'Agostino MA, De Wit M, FitzGerald O, Kvien TK, Lories R, Mease P, Nash P, Schett G, Soriano ER, Emery P.

Rheumatology (Oxford). 2017 Oct 16. doi: 10.1093/rheumatology/kex344. [Epub ahead of print]

PMID:
29045698
14.

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.

Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS.

N Engl J Med. 2017 Oct 19;377(16):1537-1550. doi: 10.1056/NEJMoa1615975.

15.

A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative.

Højgaard P, Klokker L, Orbai AM, Holmsted K, Bartels EM, Leung YY, Goel N, de Wit M, Gladman DD, Mease P, Dreyer L, Kristensen LE, FitzGerald O, Tillett W, Gossec L, Helliwell P, Strand V, Ogdie A, Terwee CB, Christensen R.

Semin Arthritis Rheum. 2018 Apr;47(5):654-665. doi: 10.1016/j.semarthrit.2017.09.002. Epub 2017 Sep 9. Review.

PMID:
29037523
16.

Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis.

Bowes J, Ashcroft J, Dand N, Jalali-Najafabadi F, Bellou E, Ho P, Marzo-Ortega H, Helliwell PS, Feletar M, Ryan AW, Kane DJ, Korendowych E, Simpson MA, Packham J, McManus R, Brown MA, Smith CH, Barker JN, McHugh N, FitzGerald O, Warren RB, Barton A.

Ann Rheum Dis. 2017 Oct;76(10):1774-1779. doi: 10.1136/annrheumdis-2017-211414. Epub 2017 Aug 18.

17.

A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis.

Tillett W, Dures E, Hewlett S, Helliwell PS, FitzGerald O, Brooke M, James J, Lord J, Bowen C, de Wit M, Orbai AM, McHugh N; PROMPT study group.

J Rheumatol. 2017 Oct;44(10):1445-1452. doi: 10.3899/jrheum.161459. Epub 2017 Aug 1.

PMID:
28765241
18.

Assisted reproductive technology in Australia and New Zealand: cumulative live birth rates as measures of success.

Chambers GM, Paul RC, Harris K, Fitzgerald O, Boothroyd CV, Rombauts L, Chapman MG, Jorm L.

Med J Aust. 2017 Aug 7;207(3):114-118.

PMID:
28764619
19.

Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.

McArdle A, Pennington S, FitzGerald O.

Clin Rev Allergy Immunol. 2017 Jul 27. doi: 10.1007/s12016-017-8630-7. [Epub ahead of print] Review.

PMID:
28748366
20.

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D.

Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.

21.

Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis.

Szentpetery A, Heffernan E, Gogarty M, Mellerick L, McCormack J, Haroon M, Elmamoun M, Gallagher P, Kelly G, Fabre A, Kirby B, FitzGerald O.

Arthritis Res Ther. 2017 Jul 5;19(1):158. doi: 10.1186/s13075-017-1364-3.

22.

The Effect of Anterior Uveitis and Previously Undiagnosed Spondyloarthritis: Results from the DUET Cohort.

O'Rourke M, Haroon M, Alfarasy S, Ramasamy P, FitzGerald O, Murphy CC.

J Rheumatol. 2017 Sep;44(9):1347-1354. doi: 10.3899/jrheum.170115. Epub 2017 Jul 1.

PMID:
28668811
23.

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.

Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD.

Ann Rheum Dis. 2017 Sep;76(9):1550-1558. doi: 10.1136/annrheumdis-2016-210724. Epub 2017 May 4.

24.

GRAPPA 2016 Project Report.

Helliwell PS, FitzGerald O, Coates LC, Callis Duffin K, Mease PJ.

J Rheumatol. 2017 May;44(5):706-710. doi: 10.3899/jrheum.170153.

PMID:
28461534
25.

Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group.

Ogdie A, de Wit M, Callis Duffin K, Campbell W, Chau J, Coates LC, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, James J, Kalyoncu U, Latella J, Lindsay C, Mease PJ, O'Sullivan D, Steinkoenig I, Strand V, Tillett W, Orbai AM.

J Rheumatol. 2017 May;44(5):697-700. doi: 10.3899/jrheum.170150.

26.

Proceedings of the GRAPPA 2016 Retreat.

Jadon DR, Gladman DD, Mease PJ, FitzGerald O, Chandran V, Goel N, Rosen CF, Maksymowych WP, Ritchlin CT, Ogdie A, Coates LC, Cauli A, Soriano ER, Husni ME, Campbell W, Azevedo VF, Callis Duffin K, Armstrong AW, Gottlieb AB, Kavanaugh A, Garg A, Helliwell PS.

J Rheumatol. 2017 May;44(5):668-673. doi: 10.3899/jrheum.170141.

PMID:
28461522
27.

A new era for collaboration?

Packham JC, Abraham S, Kirkham B, Helliwell P, Siebert S, Korendowych E, Fitzgerald O, Parkinson A, Brookes M, Coates L, McHugh N.

Rheumatology (Oxford). 2018 May 1;57(5):775-776. doi: 10.1093/rheumatology/kex083. No abstract available.

PMID:
28407115
28.

Early interventions to promote work participation in people with regional musculoskeletal pain: a systematic review and meta-analysis.

Cochrane A, Higgins NM, FitzGerald O, Gallagher P, Ashton J, Corcoran O, Desmond D.

Clin Rehabil. 2017 Nov;31(11):1466-1481. doi: 10.1177/0269215517699976. Epub 2017 Mar 27.

PMID:
28343440
29.

Effects of targeted therapies on the bone in arthritides.

Szentpétery Á, Horváth Á, Gulyás K, Pethö Z, Bhattoa HP, Szántó S, Szücs G, FitzGerald O, Schett G, Szekanecz Z.

Autoimmun Rev. 2017 Mar;16(3):313-320. doi: 10.1016/j.autrev.2017.01.014. Epub 2017 Jan 31. Review.

PMID:
28159704
30.

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.

Orbai AM, de Wit M, Mease PJ, Callis Duffin K, Elmamoun M, Tillett W, Campbell W, FitzGerald O, Gladman DD, Goel N, Gossec L, Hoejgaard P, Leung YY, Lindsay C, Strand V, van der Heijde DM, Shea B, Christensen R, Coates L, Eder L, McHugh N, Kalyoncu U, Steinkoenig I, Ogdie A.

J Rheumatol. 2017 Oct;44(10):1522-1528. doi: 10.3899/jrheum.160904. Epub 2017 Feb 1. Erratum in: J Rheumatol. 2017 Apr;44(4):543.

31.

Fatigue as a symptom in psoriasis and psoriatic arthritis: an observational study.

Tobin AM, Sadlier M, Collins P, Rogers S, FitzGerald O, Kirby B.

Br J Dermatol. 2017 Mar;176(3):827-828. doi: 10.1111/bjd.15258. Epub 2017 Feb 27. No abstract available.

PMID:
28005279
32.

Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis.

Haroon M, Winchester R, Giles JT, Heffernan E, FitzGerald O.

Clin Exp Rheumatol. 2017 Mar-Apr;35(2):270-276. Epub 2016 Dec 13.

33.

International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.

Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, Tillett W, Elmamoun M, Callis Duffin K, Campbell W, Christensen R, Coates L, Dures E, Eder L, FitzGerald O, Gladman D, Goel N, Grieb SD, Hewlett S, Hoejgaard P, Kalyoncu U, Lindsay C, McHugh N, Shea B, Steinkoenig I, Strand V, Ogdie A.

Ann Rheum Dis. 2017 Apr;76(4):673-680. doi: 10.1136/annrheumdis-2016-210242. Epub 2016 Sep 9.

34.

Implications of the diversity of class I HLA associations in psoriatic arthritis.

Winchester R, Giles J, Jadon D, Haroon M, McHugh N, FitzGerald O.

Clin Immunol. 2016 Nov;172:29-33. doi: 10.1016/j.clim.2016.07.019. Epub 2016 Jul 25.

35.

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?

Coates LC, FitzGerald O, Helliwell PS, Paul C.

Semin Arthritis Rheum. 2016 Dec;46(3):291-304. doi: 10.1016/j.semarthrit.2016.05.012. Epub 2016 Jun 2. Review.

36.

Spondyloarthropathies: IL-6 blockade in psoriatic arthritis - a new therapeutic option?

FitzGerald O.

Nat Rev Rheumatol. 2016 May 24;12(6):318-9. doi: 10.1038/nrrheum.2016.84. No abstract available.

PMID:
27215204
37.

GRAPPA 2015 Research and Education Project Reports.

Mease PJ, Helliwell PS, Boehncke WH, Coates LC, FitzGerald O, Gladman DD, Deodhar AA, Callis Duffin K.

J Rheumatol. 2016 May;43(5):979-85. doi: 10.3899/jrheum.160119.

PMID:
27134274
38.

Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting.

Orbai AM, Mease PJ, de Wit M, Kalyoncu U, Campbell W, Tillett W, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, Gossec L, Lindsay CA, Steinkoenig I, Helliwell PS, McHugh NJ, Strand V, Ogdie A.

J Rheumatol. 2016 May;43(5):965-9. doi: 10.3899/jrheum.160116.

39.

Replication of a distinct psoriatic arthritis risk variant at the IL23R locus.

Budu-Aggrey A, Bowes J, Loehr S, Uebe S, Zervou MI, Helliwell P, Ryan AW, Kane D, Korendowych E, Giardina E, Packham J, McManus R, FitzGerald O, McHugh N, Behrens F, Burkhardt H, Huffmeier U, Ho P, Martin J, Castañeda S, Goulielmos G, Reis A, Barton A.

Ann Rheum Dis. 2016 Jul;75(7):1417-8. doi: 10.1136/annrheumdis-2016-209290. Epub 2016 Mar 25. No abstract available.

40.

Perceptions of the Cause, Impact and Management of Persistent Fatigue in Patients with Rheumatoid Arthritis Following Tumour Necrosing Factor Inhibition Therapy.

Minnock P, Ringnér A, Bresnihan B, Veale D, FitzGerald O, McKee G.

Musculoskeletal Care. 2017 Mar;15(1):23-35. doi: 10.1002/msc.1136. Epub 2016 Feb 12.

PMID:
26871999
41.

Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis.

Sepriano A, Landewé R, van der Heijde D, Sieper J, Akkoc N, Brandt J, Braun J, Collantes-Estevez E, Dougados M, Fitzgerald O, Huang F, Gu J, Kirazli Y, Maksymowych WP, Marzo-Ortega H, Olivieri I, Ozgocmen S, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Van den Bosch F, van der Horst-Bruinsma I, Weber U, Wei J, Rudwaleit M; ASAS.

Ann Rheum Dis. 2016 Jun;75(6):1034-42. doi: 10.1136/annrheumdis-2015-208730. Epub 2016 Feb 10.

PMID:
26865599
42.

Striking difference of periarticular bone density change in early psoriatic arthritis and rheumatoid arthritis following anti-rheumatic treatment as measured by digital X-ray radiogrammetry.

Szentpetery A, Heffernan E, Haroon M, Kilbane M, Gallagher P, McKenna MJ, FitzGerald O.

Rheumatology (Oxford). 2016 May;55(5):891-6. doi: 10.1093/rheumatology/kev443. Epub 2016 Feb 4.

PMID:
26850991
43.

Higher Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis: A Comparison with a Control Group of Noninflammatory Rheumatologic Conditions.

Haroon M, Rafiq Chaudhry AB, Fitzgerald O.

J Rheumatol. 2016 Feb;43(2):463-4. doi: 10.3899/jrheum.150757. No abstract available.

PMID:
26834258
44.

Improving recognition of spondyloarthropathy in primary care: an unmet need.

Haroon M, FitzGerald O.

Ann Rheum Dis. 2016 Apr;75(4):e19. doi: 10.1136/annrheumdis-2016-209118. Epub 2016 Jan 28. No abstract available.

PMID:
26823529
45.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.

Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O'Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT.

Arthritis Rheumatol. 2016 May;68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.

46.

Psoriatic arthritis: complexities, comorbidities and implications for the clinic.

Haroon M, FitzGerald O.

Expert Rev Clin Immunol. 2016;12(4):405-16. doi: 10.1586/1744666X.2016.1139453. Epub 2016 Jan 28. Review.

PMID:
26735626
47.

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.

Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D.

Ann Rheum Dis. 2016 Mar;75(3):499-510. doi: 10.1136/annrheumdis-2015-208337. Epub 2015 Dec 7.

PMID:
26644232
48.

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.

Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczyński P, Vitek P, Turkiewicz A, Khraishi M, FitzGerald O, Landewé R, de Longueville M, Hoepken B, Peterson L, van der Heijde D.

RMD Open. 2015 Jun 25;1(1):e000119. doi: 10.1136/rmdopen-2015-000119. eCollection 2015.

49.

Peripheral joint involvement in psoriatic arthritis patients.

Acosta Felquer ML, FitzGerald O.

Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S26-30. Epub 2015 Oct 15. Review.

PMID:
26471860
50.

Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis.

Minnock P, Veale DJ, Bresnihan B, FitzGerald O, McKee G.

Clin Rheumatol. 2015 Nov;34(11):1857-65. doi: 10.1007/s10067-015-3088-6. Epub 2015 Oct 9.

Supplemental Content

Loading ...
Support Center